EP0204179A1 — Method for selectively increasing the ratio of single major components of teicoplanin A2 complex
Assigned to Aventis Bulk SpA · Expires 1986-12-10 · 39y expired
What this patent protects
The object of this invention is to provide a method for selectively increasing the ratio of the single TA2 major components in the T-A2 complex. More particularly, the object of this invention is a process for obtaining teicoplanin A 2 selectively enriched in any of its major co…
USPTO Abstract
The object of this invention is to provide a method for selectively increasing the ratio of the single TA2 major components in the T-A2 complex. More particularly, the object of this invention is a process for obtaining teicoplanin A 2 selectively enriched in any of its major components T-A2-1, T-A2-2, T-A2-3, T-A2-4 and T-A2-5 which .consists in adding to the culture medium of Actinoplanes teichomyceticus nov. sp. ATCC 31121 or a mutant thereof which produces T-A2 complex through the same metabolic pathway, a selectively effective amount of an appropriate precursor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.